ADO and non-small cell lung carcinoma: To better assess the utility of broad versus limited genomic testing in identifying ADO+ patients and measuring costs and benefits of treating them with targeted therapies versus missing the ADO and treating them only with standard therapy, we conducted statistical simulations to measure the population-level impact of various rates of NGS testing for patients with newly diagnosed advanced nonsquamous NSCLC in the United States where highly effective therapies are widely available to all patients.